Are Wall Street Analysts Bullish on Johnson & Johnson Stock?

Valued at a market cap of $546.9 billion, Johnson & Johnson (JNJ) is a global healthcare leader dedicated to advancing medical innovation and improving patient outcomes through its diverse portfolio of high-growth medicines and medical technologies. The New Brunswick, New Jersey-based company focuses on developing transformative therapies for complex diseases, including oncology, immunology, and neuroscience. 

This healthcare company has considerably outpaced the broader market over the past 52 weeks. Shares of JNJ have rallied 47.1% over this time frame, while the broader S&P 500 Index ($SPX) has gained 29%. Moreover, on a YTD basis, the stock is up 9.8%, compared to SPX’s 5.6% rise.